SNAP-8
Acetyl Octapeptide-3
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
SNAP-8 is a topical cosmetic peptide developed by Lipotec (now Lubrizol) as an eight-amino-acid elongation of Argireline (Acetyl Hexapeptide-8), engineered to mimic the N-terminal domain of SNAP-25 and competitively interfere with SNARE-complex assembly. Its wrinkle-reduction figures (commonly cited as roughly 35 percent depth reduction, and an eye-area value near 63 percent) trace to supplier marketing data on small in-house panels, not independent RCTs; a 2025 IJMS review of the parent compound Argireline reports that no in vivo study confirmed the peptide's proposed muscle-contraction inhibition and that hydrophilic peptides of this size barely cross the stratum corneum (one study found about 0.22 percent penetration). SNAP-8 itself has essentially no dedicated peer-reviewed efficacy trial, so the honest grade is preliminary, associated with modest anecdotal and supplier-reported benefit rather than demonstrated clinical efficacy.
- FDA
- Not FDA-approved as a drug; used only as a cosmetic ingredient. Cosmetic ingredients are not premarket-approved by FDA, and any claim to affect muscle structure or function would fall outside cosmetic status. Permitted for cosmetic use in the EU under CosIng (Regulation EC 1223/2009) as a humectant and skin-conditioning agent.
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Minimal topical risk for a legal cosmetic ingredient; efficacy is largely supplier-reported and limited by poor skin penetration.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about SNAP-8. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
A topical cosmetic peptide (INCI Acetyl Octapeptide-3), marketed as SNAP-8 and developed as an eight-residue elongation of Argireline, designed to mimic SNAP-25 and competitively dampen SNARE-mediated muscle contraction; efficacy rests mainly on supplier panels rather than independent trials.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
SNAP-8 is the next-generation version of Argireline, a topical Botox-like peptide for expression wrinkles. Like Argireline it works by gently interfering with the nerve-to-muscle signal that makes facial muscles contract, so the small repeated movements that etch in crow’s feet and frown lines are softened. It is two amino acids longer than Argireline, which is meant to make it a bit more effective.
SNAP-8, or acetyl octapeptide-3, is an eight-amino-acid cosmetic peptide developed by the same company behind Argireline as its enhanced successor. It mimics a fragment of SNAP-25, a protein in the cellular machinery that releases the neurotransmitter triggering muscle contraction.
- Type
- Cosmetic neuropeptide
- Identity
- Acetyl octapeptide-3
- Mechanism
- SNARE modulation
- Vs Argireline
- ~30% more active (maker)
- Limit
- Poor penetration
- Status
- Cosmetic
Argireline’s Bigger Sibling, Same Penetration Problem
SNAP-8 shares Argireline’s mechanism almost exactly, competing with the SNAP-25 protein to destabilize the complex that releases acetylcholine, so it is a topical and far gentler cousin of Botox aimed at dynamic wrinkles. Its two extra amino acids let it mimic a larger piece of the target, and manufacturer comparisons claim it is roughly thirty percent more active than Argireline, with studies reporting wrinkle-depth reductions around the eyes. The honest qualifiers are Argireline’s qualifiers. Much of the supporting evidence is manufacturer-sponsored, the effects are modest, and most importantly these peptides penetrate the skin poorly, which limits how much actually reaches the nerve endings, so real-world results tend to fall short of the headline numbers. It is a safe, incremental improvement on a cosmetic peptide whose core limitation it inherits.
Safety in detail
SNAP-8 is a topical cosmetic peptide with a benign safety profile at cosmetic use levels and no botulinum-like systemic toxicity, since it is a weak SNARE-competitive mimetic rather than a toxin. The main honest caveat is efficacy, not safety: independent evidence that it reaches the neuromuscular junction and measurably smooths dynamic wrinkles is weak, and headline percentages come from the manufacturer.
- It has an excellent safety profile: non-irritating, non-sensitizing, with no systemic absorption at cosmetic concentrations.
- It causes no muscle paralysis, unlike injected botulinum toxin.
- Its main limitation is modest efficacy and poor penetration, not harm.
- Much of its efficacy evidence is manufacturer-sponsored.
Children and teenagers
SNAP-8 is a cosmetic anti-wrinkle ingredient with no pediatric relevance and no appropriate pediatric use.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
SNAP-8 reaches users through the over-the-counter cosmetic market, formulated into anti-wrinkle serums and creams, the same economy as Argireline. It is a mainstream cosmetic ingredient, with its modest, partly manufacturer-backed evidence forming part of the pitch.
How we got here
SNAP-8 was created by the Spanish peptide house Lipotec (later acquired by Lubrizol) as a deliberate elongation of its earlier product Argireline (Acetyl Hexapeptide-8), extending the chain from six to eight residues so that it more fully mimics the N-terminal domain of SNAP-25 within the SNARE complex. Both peptides descend from the same design idea of a topical, far gentler alternative to botulinum toxin for expression lines. After the original patents lapsed the ingredient became widely second-sourced under the INCI name Acetyl Octapeptide-3 and the vendor label SNAP-8, appearing in serums, eye creams and masks worldwide; the same material also circulates in the research-chemical and DIY-cosmetic supply chain under its CAS number and sequence name.
SNAP-8 was developed by the company behind Argireline as a next-generation version, adding two amino acids to the original hexapeptide to better mimic the target protein, and it entered the cosmetic market as an enhanced anti-wrinkle ingredient.
The numbers behind the grade
- Type
- Cosmetic neuropeptide
- Identity
- Acetyl octapeptide-3
- Mechanism
- SNARE
- Vs Argireline
- Slightly more potent
- Limit
- Penetration
- Status
- Cosmetic
The people taking it
The eight-amino-acid successor to Argireline, a topical Botox-like wrinkle peptide that is marginally more potent on paper but inherits the same poor skin penetration and modest real-world effect.
SNAP-8’s users are anti-aging skincare consumers targeting expression lines, often the same crowd choosing between or stacking it with Argireline and the collagen peptides.
A widely-used over-the-counter anti-wrinkle cosmetic peptide, the enhanced successor to Argireline, delivering modest softening of expression lines limited by skin penetration.
Set against the alternatives
SNAP-8 is the slightly larger, slightly more potent successor to Argireline, sharing the same neuromuscular mechanism and the same penetration ceiling. Against actual Botox it is vastly weaker and works topically rather than by injection. Against the collagen-stimulating Matrixyl and the anti-inflammatory Palmitoyl Tetrapeptide-7, it targets a different lever, muscle movement, and is often combined with them. Its identity is Argireline’s, incrementally improved.
What we do not know
- How much of the manufacturer potency advantage survives the penetration limit in practice.
- Whether better delivery systems could meaningfully improve results.
- How it performs in independent rather than manufacturer studies.
Legal status
SNAP-8 is a widely available over-the-counter cosmetic ingredient, not a drug, formulated at low single-digit percentages in serums and creams. Its effect is limited by skin penetration.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
SNAP-8 is a safe, mainstream cosmetic peptide, a marginally stronger successor to Argireline that shares its poor-penetration limitation. Anyone considering it should read the Argireline entry, expect modest softening of expression lines rather than Botox-like results, and not pay a premium on the strength of manufacturer potency claims.
SNAP-8 is inexpensive to moderately priced across over-the-counter products and is broadly accessible.
SNAP-8 comes from cosmetic-ingredient suppliers and appears in many over-the-counter products, with formulation quality varying.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about SNAP-8.
- Timeline. We have not built the dated record of research and regulatory events.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
Sources
SNAP-8 is Acetyl Octapeptide-3, a synthetic anti-wrinkle cosmetic peptide, and a newer, larger relative of Argireline (Acetyl Hexapeptide-8) that influences the muscle-contraction process; efficacy claims are manufacturer-sourced, not independently confirmed
2025 peer-reviewed review of Argireline (parent peptide) reports no in vivo study confirmed the proposed muscle-contraction inhibition, and that hydrophilic peptides of this size barely cross the lipophilic stratum corneum (about 0.22 percent penetration in one study)
Official CosIng/INCI record for Acetyl Octapeptide-3 lists functions as Humectant and Skin Conditioning agent; it is a permitted (regulated) EU cosmetic ingredient, not a medicine
EU CosIng is the official European Commission cosmetic-ingredient database under Regulation (EC) No 1223/2009 governing ingredients such as Acetyl Octapeptide-3
SpecialChem INCI profile lists Acetyl Octapeptide-3 with CosIng REF No. 54131 and CosIng functions Humectant and Skin Conditioning
Mechanism description: SNAP-8 mimics part of SNAP-25 and competitively interferes with SNARE-complex assembly to attenuate facial muscle contraction, a gentler and far weaker pathway than botulinum toxin
Development and identity: SNAP-8 was developed by Lipotec (now part of Lubrizol); CAS 868844-74-0; sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 engineered to mimic the N-terminal domain of SNAP-25; suppliers proliferated after patent expiry
Evidence caveat: manufacturer-funded panels report roughly 30 to 60 percent wrinkle-depth reduction while independent observation suggests more modest 10 to 20 percent improvement, and topical penetration to the neuromuscular junction is uncertain
Supplier-reported comparative panel: SNAP-8 reduced wrinkles about 34.98 percent versus 27.05 percent for Argireline over 28 days twice daily in 17 women (manufacturer claim), and an eye-area figure near 63 percent is quoted from supplier data
The studies that matter
Mechanismestablished
SNAP-8 competes with SNAP-25 to reduce acetylcholine release and soften muscle-driven wrinkles, like Argireline.
Potency claimmanufacturer
Maker comparisons report roughly thirty percent greater activity than Argireline at equal concentration.
Penetration limitknown
Like Argireline, poor skin penetration limits how much reaches the target, so real effects are modest.